MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC

Breast cancer is the most common malignancy among women worldwide. Triple-negative breast cancer (TNBC), defined by the lack of estrogen receptor, progesterone receptor, and HER2 expression, comprises approximately 15% of all breast cancers and is the most aggressive subtype, associated with a higher risk of early recurrence and death compared to other breast cancer subtypes. Neoadjuvant chemotherapy (NACT), administered before definitive surgery, is the standard of care for stage II-III TNBC (eTNBC), and pathological complete response (pCR), defined as the absence of invasive cancer in the br

Trial Details

NCT ID
NCT07327021
Phase
PHASE2
Sponsor
Tel-Aviv Sourasky Medical Center
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Treatment De-Escalation and Early Surgery
Locations (sample)
  • Tel Aviv, Israel|32.08088,34.78057
  • Tel Litwinsky, Israel|32.05096,34.84588

Key Eligibility Criteria

  • Patient is eligible per physician's discretion for the KEYNOTE-522 regimen (Neoadjuvant paclitaxel-carboplatin-doxorubicin-cyclophosphamide-pembrol…
  • Signed written informed consent
  • Histologically confirmed primary infiltrating breast cancer with estrogen receptor expression \<1%, Progesterone receptor expression \<1%, and with…
  • T2-3N0, T1-3N1 disease according to TNM-staging (8th edition, AJCC).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →